Are you getting the attention you need from your current central lab?

Barc Lab aspires to partner with you to develop bespoke, optimized solutions for your projects to ensure success of your treatments and improve patients’ lives. With more than 35 years of experience, 375 ongoing clinical trials, and divisions in 5 continents, we have the expertise, scientific knowledge, and technology needed to help you achieve your goals. 

THERAPEUTIC AREAS

We can meet you anywhere to deliver a unique plan for any of these key therapeutic areas, and support clients in every step of their clinical trials.

Our mission is to partner with you to bring personalized medicine to patients and
allow you to focus on what matters most: Improving healthcare and quality of life.

Oncology

As a global leader in oncology trials, we can keep you on track and beyond in this ever-evolving field.

NASH

We support the biggest phase 3 study in NASH so far, in search of a better diagnosis and treatment.

Infectious diseases

We offer flexible assays, fast and secure diagnostic opportunities, and can react quickly to new
infectious threats with the development of new tests.

Inflammatory disorders

Our specialists are committed to help you determine which tests could be implemented making your
study in inflammatory disorders more informative and less risky.

We can provide you with the solution you need by tapping on to our broad testing portfolio, ranging from Flow Cytometry, Histopathology, PK and Biomarker testing, NGS, Microbiology and any other esoteric & routing testing.

Learn more

Go to article: Home | The power of patientsGo to article: Scandinavian Health Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: NSFGo to article: ContentsGo to article: CapsugelGo to article: Capsugel Company Insight Go to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: Molnar Company InsightGo to article: Molnar-InstituteGo to article: A costly oversight: the ongoing impact of the valsartan recallGo to article: Novo Nordisk Company InsightGo to article: Novo NordiskGo to article: Where is the UK’s supply of Migraleve?Go to article: Dupont PharmaceuticalsGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Charting the life and times of the EMA as it leaves LondonGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: CBD: the myth, the magic and the real deal drugsGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: How do cancer cells communicate and can it help us catch them?Go to article: HOF SonderanlagenbauGo to article: HOF Sonderanlagenbau Company Insight Go to article: Buyers’ clubs: the first step toward universal UK access to Orkambi?Go to article: SterigenicsGo to article: Owen MumfordGo to article: Are we nearing the end of animal testing in pharma?Go to article: Zenatek Go to article: Barc Lab Go to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Abiogen PharmaGo to article: MimotopesGo to article: Next issue